Anti-viral therapy for prevention of perinatal HBV transmission: Extending therapy beyond birth does not protect against post-partum flare

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 10, 2014, Pages 1225-1234

  Nguyen, V ^a   Tan, P K ^a   Greenup, A J ^a   Glass, A ^a   Davison, S ^a   Samarasinghe, D ^b   Holdaway, S ^b   Strasser, S I ^c   Chatterjee, U ^d   Jackson, K ^e   Locarnini, S A ^e   Levy, M T ^a  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG POTENCY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PERINATAL INFECTION; PRIORITY JOURNAL; PUERPERIUM; SEROCONVERSION; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS LOAD;

ADENINE; ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84899078129     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12726     Document Type: Article

References (35)

1. World Health Organization, Hepatitis B. World Health Organization fact sheet 204, 2008.
2. Chen CJ, Wang LY, Yu MW,. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 (Suppl.): E3-6.
3. Beasley RP, Hwang LY, Lee GC, et al,. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-102.
4. del Canho R, Grosheide PM, Mazel JA, et al,. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-30.
5. Chen DS,. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-16.
6. Song YM, Sung J, Yang S, et al,. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007; 166: 813-8.
7. van Zonneveld M, van Nunen AB, Niesters HG, et al,. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-7.
8. Shi Z, Yang Y, Ma L, et al,. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 147-59.
9. Ip HM, Lelie PN, Wong VC, et al,. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet 1989; 1: 406-10.
10. Wiseman E, Fraser MA, Holden S, et al,. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-92.
11. Zou H, Chen Y, Duan Z, et al,. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012; 19: e18-25.
12. European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
13. Petersen J,. HBV treatment and pregnancy. J Hepatol 2011; 55: 1171-3.
14. Tran TT,. Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med 2009; 76 (Suppl. 3): S25-9.
15. Levy MT,. Preventing perinatal transmission of HBV: an Australian perspective. Current Hepatitis Reports 2012; 11: 206-12.
16. Garcia Angel AL,. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann Hepatol 2006; 5: 184-6.
17. Guidotti LG, Chisari FV,. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
18. Gaunt G, Ramin K,. Immunological tolerance of the human fetus. Am J Perinatol 2001; 18: 299-312.
19. Giles ML, Visvanathan K, Lewin SR, et al,. Chronic hepatitis B infection and pregnancy. Obstet Gynecol Surv 2012; 67: 37-44.
20. ter Borg MJ, Leemans WF, de Man RA, et al,. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41.
21. Soderstrom A, Norkrans G, Lindh M,. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003; 35: 814-9.
22. Lin HH, Chen PJ, Chen DS, et al,. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol 1989; 29: 1-6.
23. Xu WM, Cui YT, Wang L, et al,. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
24. Honkoop P, de Man RA, Niesters HG, et al,. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-9.
25. Jin YJ, Kim KM, Yoo DJ, et al,. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J 2012; 9: 239.
26. Dienstag JL, Schiff ER, Wright TL, et al,. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
27. Pan CQ, Han GR, Jiang HX, et al,. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10: 520-6.
28. Ayres A, Yuen L, Jackson KM, et al,. Short duration of lamivudine for prevention of HBV transmission in pregnancy: lack of potency and selection of resistant mutations. J Viral Hepat 2013; doi: 10.1111/jvh.12212 [Epub ahead of print].
29. Ayres A, Locarnini S, Bartholomeusz A,. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004; 95: 125-49.
30. Han GR, Cao MK, Zhao W, et al,. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol, 2011; 55: 1213-21.
31. Giles M, Visvanathan K, Lewin SR, et al,. Clinical and virological factors that predict post partum flares in pregnant women with chronic HBV. (2013) HBV Natural History and Outcomes. Hepatology 2013; 58: 638A.
32. Carey I, Horner M, Bruce MJ, et al,. Chronic hepatitis B in pregnancy-can virological, serological and immunological markers during pregnancy predict post delivery hepatic flares? (2013) HBV Natural History and Outcomes. Hepatology 2013; 58: 643A.
33. Perrillo R,. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49: S103-11.
34. Boni C, Penna A, Ogg GS, et al,. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-71.
35. Boni C, Penna A, Bertoletti A, et al,. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.